ストックスクリーナーアプリを入手
1.41
2.17%
0.03
プレマーケット:
1.44
0.03
+2.13%
前日終値:
$1.38
開ける：
$1.51
24時間の取引高:
2.36M
Relative Volume:
2.60
時価総額：
$150.32M
収益：
$45.44M
当期純損益:
$-35.43M
株価収益率:
-4.1471
EPS:
-0.34
ネットキャッシュフロー:
$-25.39M
1週間 パフォーマンス:
-1.40%
1か月 パフォーマンス:
-37.05%
6か月 パフォーマンス:
-66.19%
1年 パフォーマンス:
-64.30%
1日の値動き範囲:
$1.38
$1.54
1週間の範囲:
$1.26
$1.54
52週間の値動き範囲:
$1.26
$5.20
Maxcyte Inc Stock (MXCT) Company Profile
MXCT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
1.41 | 147.12M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
129.28 | 225.22B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
104.15 | 151.88B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
378.52 | 144.88B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
91.98 | 119.04B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.18 | 45.61B | 5.69B | 1.41B | 577.90M | 6.95 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-11 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-08-07 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-07-22 | 開始されました | Stephens | Overweight |
| 2023-11-29 | 開始されました | Craig Hallum | Buy |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-08-24 | 開始されました | BTIG Research | Buy |
| 2021-08-24 | 開始されました | Cowen | Outperform |
| 2021-08-24 | 開始されました | Stephens | Overweight |
| 2021-08-24 | 開始されました | Stifel | Buy |
| 2021-08-24 | 開始されました | Wedbush | Outperform |
| 2021-08-24 | 開始されました | William Blair | Outperform |
すべてを表示
Maxcyte Inc (MXCT) 最新ニュース
What machine learning models say about MaxCyte Inc.IPO Watch & Reliable Breakout Forecasts - Newser
Why MaxCyte Inc. is moving todayJuly 2025 Catalysts & Free Safe Entry Trade Signal Reports - Newser
What MACD and RSI say about MaxCyte Inc.2025 Biggest Moves & Fast Moving Market Watchlists - Newser
Analyzing the Impact of Earnings Reports on MaxCyte Inc Inc. (MXCT) Price Performance - investchronicle.com
Signal strength of MaxCyte Inc. stock in tech scannersWeekly Trade Analysis & Capital Efficiency Focused Ideas - Newser
Maxcyte Stock Soars 10.87% on Insider Buying - AInvest
Volume spikes in MaxCyte Inc. stock – what they meanIPO Watch & Weekly Top Stock Performers List - Newser
Custom strategy builders for tracking MaxCyte Inc.Treasury Yields & Safe Swing Trade Setup Alerts - Newser
Douglas buys $111k in Maxcyte shares By Investing.com - Investing.com South Africa
Masoud Maher buys Maxcyte (MXCT) shares worth $102,915 - Investing.com
Maxcyte CFO Swirsky buys $64.5k in shares - Investing.com
Erck Stanley C, Maxcyte director, buys $137k in MXCT stock - Investing.com
Maxcyte Director and CFO Make Significant Stock Purchases. - AInvest
MaxCyte Executives and Directors Acquire Shares - TradingView
Should value investors consider MaxCyte Inc.Game-Changing Investment Alerts - thegnnews.com
Will MaxCyte Inc. continue its uptrendJuly 2025 Trends & Stepwise Trade Signal Implementation - Newser
MaxCyte (NASDAQ:MXCT) Earns Neutral Rating from BTIG Research - Defense World
MaxCyte Inc. Breaks Losing Streak — Is the Trend ReversingFree Premium Stock Market Reports - beatles.ru
Chart based exit strategy for MaxCyte Inc.Oversold Stock Bounce Playbook Generator - Newser
Chartists Watching For Breakout in MaxCyte Inc.Weekly Return Pick Forecast Reports Show Trend - beatles.ru
MaxCyte Chief Commercial Officer Departs Amid Severance Agreement - TipRanks
BTIG Downgrades MaxCyte to Neutral Citing Ongoing Challenges for Cell and Gene Therapy Customers - AInvest
MaxCyte Shares Plummet After Analyst Downgrades and Missed Earnings Estimates - AInvest
MaxCyte Shares Fall After BTIG Downgrade - MarketScreener
MaxCyte Signs Strategic Platform License with Adicet Bio for Cancer and Autoimmune Diseases Treatments. - AInvest
MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio - Yahoo Finance
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Benzinga
BTIG Downgrades MaxCyte to Neutral From Buy - MarketScreener
MaxCyte stock rating downgraded to Neutral by BTIG on funding concerns - Investing.com Nigeria
MaxCyte signs platform license agreement with Adicet Bio for Gamma Delta T cell therapies - SelectScience
MaxCyte signs platform license agreement with Adicet Bio - MSN
MaxCyte (NASDAQ:MXCT) Lowered to Sell Rating by Wall Street Zen - Defense World
MaxCyte Inc Q2 2025 Earnings: Revenue Falls Short at $8.5 Million, Net Loss Widens to $12.4 Million - AInvest
MaxCyte, Inc. (NASDAQ:MXCT) Q2 2025 Earnings Call Transcript - Insider Monkey
Maxcyte, Inc. shares rise 1.40% after-hours despite William Blair downgrading to Market Perform. - AInvest
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates - MSN
MaxCyte revises 2025 core revenue guidance to $29.5M-$32.5M amid customer program consolidation - MSN
Maxcyte's 31% Intraday Plunge: Earnings Woes and Sector Turbulence Spark Investor Panic - AInvest
MaxCyte Disappoints With Lower Revenue And Guidance For 2025 - Finimize
William Blair Downgrades MaxCyte to Market Perform From Outperform - MarketScreener
MaxCyte downgraded to Market Perform from Outperform at William Blair - TipRanks
Maxcyte, Inc. shares fall 11.76% premarket after Q2 revenue misses analyst estimates. - AInvest
MaxCyte stock downgraded by William Blair to Market Perform on weak guidance - Investing.com Australia
MaxCyte's Q2 2025 Earnings Call: Unpacking Key Contradictions in Growth and Manufacturing Strategy - AInvest
MaxCyte Updates 2025 Revenue Guidance to $29.5M-$32.5M Amid Customer Program Consolidation - AInvest
Earnings call transcript: MaxCyte misses Q2 revenue forecast amidst stock dip - Investing.com
MaxCyte (MXCT) Q2 Revenue Drops 18% - AOL.com
Maxcyte 2025 Q2 Earnings Worse Performance as Net Loss Widens 31.8% - AInvest
MaxCyte Q3 2025 presentation slides: SPL portfolio expands despite market challenges - Investing.com Nigeria
MaxCyte Q3 2025 presentation slides: SPL portfolio expands despite market challenges By Investing.com - Investing.com South Africa
Cell-engineering firm MaxCyte Q2 revenue misses analyst estimates - MarketScreener
Maxcyte Inc (MXCT) 財務データ
収益
当期純利益
現金流量
EPS
Maxcyte Inc (MXCT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Masoud Maher | President and CEO |
Aug 13 '25 |
Buy |
1.37 |
75,000 |
102,915 |
175,000 |
| Erck Stanley C | Director |
Aug 13 '25 |
Buy |
1.37 |
100,000 |
137,220 |
398,328 |
| DOUGLAS RICHARD | Director |
Aug 13 '25 |
Buy |
1.39 |
80,000 |
111,040 |
230,577 |
| Brooke William W | Director |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
150,879 |
2.30%
0.38%
大文字化:
|
ボリューム (24 時間):